Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.
Jules Cohen, MD
Advertisement
Articles by Jules Cohen, MD
Recent trials highlight T-DXd's superior efficacy and manageable toxicity in treating high-risk HER2-positive breast cancer, reshaping treatment strategies.
Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.
Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
2
Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data
3
Disparities Drive Shifting Pancreatic Cancer Survival Trends
4
Postpandemic Nursing Home Capacity Declines Tied to Longer Hospital Stays, Increased Patient Travel
5
